Longitudinal cystic fibrosis care

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 86-97

  Antunovic, S S ^a,b   Lukac, M ^a,b   Vujovic, D ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIKACIN; ATALUREN; AZITHROMYCIN; AZTREONAM; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORNASE ALFA; ELUBRIXIN; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; IBUPROFEN; IMIPENEM; IVACAFTOR; LEVOFLOXACIN; LUMACAFTOR; MANNITOL; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; RETINOL; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VITAMIN D; VITAMIN K GROUP; VR 496; VX 661;

ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; NEWBORN SCREENING; NUTRITIONAL ASSESSMENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REPRODUCTION; RESPIRATORY TRACT DISEASE;

CYSTIC FIBROSIS; GENETIC COUNSELING; GENETIC THERAPY; HUMANS; INFANT, NEWBORN; LONGITUDINAL STUDIES; NEONATAL SCREENING; PROGRESSIVE PATIENT CARE;

EID: 84871327041     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.183     Document Type: Article

References (75)

1. Sferra, T.J. & Collins, F.S. The molecular biology of cystic fibrosis. Annu. Rev. Med. 44, 133-144 (1993).
2. Gustafsson P. Cystic fibrosis in focus. Respiration 67, 2 (2000).
3. Griesenbach, U., Geddes, D.M. & Alton, E.W. Gene therapy progress and prospects: Cystic fibrosis. Gene Ther. 13, 1061-1067 (2006).
4. Simon-Bouy, B. et al. Hyperechogenic fetal bowel: A large French collaborative study of 682 cases. Am. J. Med. Genet. A 121A, 209-213 (2003).
5. Muller, F., Simon-Bouy, B., Girodon, E., Monnier, N., Malinge, M.C. & Serre, J.L. Predicting the risk of cystic fibrosis with abnormal ultrasound signs of fetal bowel: Results of a French molecular collaborative study based on 641 prospective cases. Am. J. Med. Genet. 110, 109-115 (2002).
6. de Becdelievre, A. et al. Comprehensive description of CFTR genotypes and ultrasound patterns in 694 cases of fetal bowel anomalies: A revised strategy. Hum. Genet. 129, 387-396 (2011).
7. Zeitlin, P.L. Pharmacologic restoration of delta F508 CFTR-mediated chloride current. Kidney Int. 57, 832-837 (2000).
8. Gan, K.H. et al. A cystic fibrosis mutation associated with mild lung disease. N. Engl. J. Med. 333, 95-99 (1995).
9. A hmed, N. et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 52, 1159-1164 (2003).
10. Dawson, K.P., Frossard, P.M. & Al-Awar, B. Disease severity associated with cystic fibrosis mutations deltaF508 and S549R(T->G). East. Mediterr. Health J. 7, 975-980 (2001).
11. Rowe M.S., Stacey M., Sorscher J.E. Mechanisms of disease: Cystic fibrosis. N. Engl. J. Med. 352, 992-2001 (2005).
12. Grody W.W.et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 3, 149-154 (2001).
13. Chillon, M. et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332, 1475-1480 (1995).
14. O'Sallivan P.B., Freedman D.S. Cystic fibrosis. Lancet 373, 1891-1904 (2009).
15. Blackman, S.M. et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 131, 1030-1039 (2006).
16. A merican College of Obstetricians and Gynecologists Committee on Genetics. ACOG committee opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet. Gynecol. 117, 1028 (2011).
17. Castellani, C., Picci, L., Tamanini, A., Girardi, P., Rizzotti, P. & Assael, B.M. Association between carrier screening and incidence of cystic fibrosis. JAMA 302, 2573-2579 (2009).
18. Fragouli, E. Preimplantation genetic diagnosis: Present and future. J. Assist. Reprod. Genet. 24, 201-207 (2007).
19. Kharazzi M., Kharazzi L. Delayed diagnosis of cystic fibrosis and the family perspective. J. Pediatr. 147, S21-S25 (2005).
20. A ccurso, F.J., Sontag, M.K. & Wagener, J.S. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J. Pediatr. 147, S37-S41 (2005).
21. Comeau, A.M. et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 119, e495-e518 (2007).
22. Parad, R.B. & Comeau, A.M. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J. Pediatr. 147, S78-S82 (2005).
23. Parad, R.B. et al. Sweat testing infants detected by cystic fibrosis newborn screening. J. Pediatr. 147, S69-S72 (2005).
24. Comeau, A.M. et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: A cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113, 1573-1581 (2004).
25. Padman, R. et al. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics 119, e531-e537 (2007).
26. Mall, M. et al. Defective cholinergic Cl(-) secretion and detection of K(+secretion in rectal biopsies from cystic fibrosis patients. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G617-G624 (2000).
27. Pares, A. et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCACooperative Group from the Spanish Association for the Study of the Liver. J. Hepatol. 32, 561-566 (2000).
28. Walkowiak, J. et al. Early decline of pancreatic function in cystic fibrosis patients with class 1 or 2 CFTR mutations. J. Pediatr. Gastroenterol. Nutr. 40, 199-201 (2005).
29. Weintraub, A. et al. Exocrine pancreatic function testing in patients with cystic fibrosis and pancreatic sufficiency: A correlation study. J. Pediatr. Gastroenterol. Nutr. 48, 306-310 (2009).
30. Borowitz, D. et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J. Pediatr. 155, S73-S93 (2009).
31. Borowitz, D. et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J. Pediatr. 149, 658-662 (2006).
32. Borowitz, D., Baker, R.D. & Stallings, V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 35, 246-259 (2002).
33. Sagel, S.D. & Accurso, F.J. Monitoring inflammation in CF. Cytokines. Clin. Rev. Allergy Immunol. 23, 41-57 (2002).
34. Tepper, R.S., Weist, A., Williams-Nkomo, T. & Kisling, J. Elastic properties of the respiratory system in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 170, 505-507 (2004).
35. Schechter, M.S. Nongenetic influences on cystic fibrosis outcomes. Curr. Opin. Pulm. Med. 17, 448-454 (2011).
36. van der Doef, H.P., Arets, H.G., Froeling, S.P., Westers, P. & Houwen, R.H. Gastric acid inhibition for fat malabsorption or gastroesophageal reflux disease in cystic fibrosis: Longitudinal effect on bacterial colonization and pulmonary function. J. Pediatr. 155, 629-633 (2009).
37. Kleinman, R.E. & Fracchia, M.S. Vitamin K and cystic fibrosis: Give me a double, please. Am. J. Clin. Nutr. 92, 469-470 (2010).
38. Kasarskis, E.J. & Bass, N.H. Benign intracranial hypertension induced by deficiency of vitamin A during infancy. Neurology 32, 1292-1295 (1982).
39. Y alcin, E., Kiper, N., Dogru, D., Ozcelik, U. & Aslan, A.T. Clinical features and treatment approaches in cystic fibrosis with pseudo-Bartter syndrome. Ann. Trop. Paediatr. 25, 119-124 (2005).
40. Castellani, C. et al. European best practice guidelines for cystic fibrosis neonatal screening. J. Cyst. Fibros. 8, 153-173 (2009).
41. Malfroot, A. et al. Immunisation in the current management of cystic fibrosis patients. J. Cyst. Fibros. 4, 77-87 (2005).
42. Littlewood, J.M., Wolfe, S.P. & Conway, S.P. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr. Pulmonol. 41, 35-49 (2006).
43. Gullo, L., Graziano, L., Babbini, S., Battistini, A., Lazzari, R. & Pezzilli, R. Faecal elastase 1 in children with cystic fibrosis. Eur. J. Pediatr. 156, 770-772 (1997).
44. Cipolli, M. et al. Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Arch. Dis. Child. 92, 842-846 (2007).
45. Sinaasappel, M. et al. Nutrition in patients with cystic fibrosis: A European Consensus. J. Cyst. Fibros. 1, 51-75 (2002).
46. Fahy, J.V. & Dickey, B.F. Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2233-2247 (2010).
47. Royce, F.H. & Carl, J.C. Health-related quality of life in cystic fibrosis. Curr. Opin. Pediatr. 23, 535-540 (2011).
48. Lazaar, A.L., Sweeney, L.E., MacDonald, A.J., Alexis, N.E., Chen, C. & Tal-Singer, R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br. J. Clin. Pharmacol. 72, 282-293 (2011).
49. Rogers, G.B., Hoffman, L.R. & Doring, G. Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J. Cyst. Fibros. 10, 387-400 (2011).
50. Starner, T.D. & McCray, P.B. Jr. Pathogenesis of early lung disease in cystic fibrosis: A window of opportunity to eradicate bacteria. Ann. Intern. Med. 143, 816-822 (2005).
51. Flume, P.A. et al. Cystic fibrosis pulmonary guidelines: Airway clearance therapies. Respir. Care 54, 522-537 (2009).
52. Sermet-Gaudelus, I., Mayell, S.J. & Southern, K.W. Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening. J. Cyst. Fibros. 9, 323-329 (2010).
53. Flume, P.A. et al. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176, 957-969 (2007).
54. Lo, D., VanDevanter, D.R., Flume, P. & Smyth, A. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: Continuous or intermittent? Respir. Med. 105(suppl. 2), S9-17 (2011).
55. Y ousef, A.A. & Jaffe, A. The role of azithromycin in patients with cystic fibrosis. Paediatr. Respir. Rev. 11, 108-114 (2010).
56. Oomen, K.P. & April, M.M. Sinonasal manifestations in cystic fibrosis. Int. J. Otolaryngol. 2012, 789572 (2012).
57. Colombo, C., Ellemunter, H., Houwen, R., Munck, A., Taylor, C. & Wilschanski, M. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J. Cyst. Fibros. 10(suppl. 2), S24-S28 (2011).
58. Bansi, D.S., Price, A., Russell, C. & Sarner, M. Fibrosing colonopathy in an adult owing to over use of pancreatic enzyme supplements. Gut 46, 283-285 (2000).
59. Boyle, M.P. Adult cystic fibrosis. JAMA 298, 1787-1793 (2007).
60. Braun, A.T. & Merlo, C.A. Cystic fibrosis lung transplantation. Curr. Opin. Pulm. Med. 17, 467-472 (2011).
61. Rowland, M. et al. Outcome in cystic fibrosis liver disease. Am. J. Gastroenterol. 106, 104-109 (2011).
62. Conklin, L., Zeitlin, P.L. & Cuffari, C. Cystic fibrosis presenting as recurrent pancreatitis in a young child with a normal sweat test and pancreas divisum: A case report. J. Med. Case Rep. 2, 176 (2008).
63. Freedman, S.D., Uppot, R.N. & Mino-Kenudson, M. Case records of the Massachusetts General Hospital. Case 26-2009. A 34-year-old man with cystic fibrosis with abdominal pain and distention. N. Engl. J. Med. 361, 807-816 (2009).
64. O'Riordan S.M., Robinson P.D., Donaghue K.C., Moran A.M. Management of cystic fibrosis-related diabetes. Pediatr Diabetes 9, 338-344 (2008).
65. A ris, R.M. et al. Guide to bone health and disease in cystic fibrosis. J. Clin. Endocrinol. Metab. 90, 1888-1896 (2005).
66. Hardin, D.S., Ellis, K.J., Dyson, M., Rice, J., McConnell, R. & Seilheimer, D.K. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: Results of a randomized controlled trial. J. Pediatr. 139, 636-642 (2001).
67. McMullen, A.H. et al. Impact of pregnancy on women with cystic fibrosis. Chest 129, 706-711 (2006).
68. Sawicki, G.S. & Tiddens, H. Managing treatment complexity in cystic fibrosis: Challenges and opportunities. Pediatr. Pulmonol. 47, 523-533 (2012).
69. Becq, F., Mall, M.A., Sheppard, D.N., Conese, M. & Zegarra-Moran, O. Pharmacological therapy for cystic fibrosis: From bench to bedside. J. Cyst. Fibros. 10(suppl. 2), S129-S145 (2011).
70. Ledford, H. Drug bests cystic-fibrosis mutation. Nature 482, 145 (2012).
71. Ramsey, B.W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011).
72. Kaiser J. New cystic fibrosis drug offers hope, at a price. Science 335, 645 (2012).
73. Davis, P.B. Therapy for cystic fibrosis-the end of the beginning? N. Engl. J. Med. 365, 1734-1735 (2011).
74. Opar, A. Excitement mounts for first disease-modifying cystic fibrosis drugs. Nat. Rev. Drug Discov. 10, 479-480 (2011).
75. Davies, J.C. & Alton, E.W. Gene therapy for cystic fibrosis. Proc. Am. Thorac. Soc. 7, 408-414 (2010).